Podcasts about hematopoietic

Hematopoietic stem cells (HSCs) normally reside in the bone marrow niche but can traffic across the bone marrow endothelium into the bloodstream to populate different niches. This process of HSC mobilization from the bone marrow to the blood, is an increasingly favored procedure to obtain HSCs for hematopoietic cell transplantation therapy. Though mobilization is robust in many donors due to years of refined protocols and drug combinations, the process remains difficult or contraindicated among substantial patient subgroups. Using the current standard of care, up to 30% of patients fail to mobilize HSCs and some patients cannot tolerate the current mobilization procedures. Today's guests will discuss their research using vascular endothelial growth factor, known as VEGF, as an alternative method of mobilization, the mechanisms underlying it, and the implications for improving patient outcomes.GuestsStephanie Smith-Berdan, MS, Institute for the Biology of Stem Cells, Department of Biomolecular, Engineering, University of California, Santa Cruz, USA. Camilla Forsberg, PhD, Institute for the Biology of Stem Cells, Department of Biomolecular Engineering, University of California, Santa Cruz, USA. HostJanet Rossant, Editor-in-Chief, Stem Cell Reports and The Gairdner FoundationSupporting ContentPaper link: Vascular endothelial growth factor-induced vascular permeability results in drastic and reversible hematopoietic stem cell mobilization, Stem Cell ReportsAbout Stem Cell ReportsStem Cell Reports is the open access, peer-reviewed journal of the International Society for Stem Cell Research (ISSCR) for communicating basic discoveries in stem cell research, in addition to translational and clinical studies. Stem Cell Reports focuses on original research with conceptual or practical advances that are of broad interest to stem cell biologists and clinicians.X: @StemCellReportsAbout ISSCRWith nearly 5,000 members from more than 80 countries, the International Society for Stem Cell Research (@ISSCR) is the preeminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The ISSCR mission is to promote excellence in stem cell science and applications to human health.ISSCR StaffKeith Alm, Chief Executive OfficerYvonne Fisher, Managing Editor, Stem Cell ReportsKym Kilbourne, Director of Media and Strategic CommunicationsMegan Koch, Senior Marketing ManagerJack Mosher, Scientific DirectorHunter Reed, Senior Marketing Coordinator

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Sean Morrison, Ph.D., from the Children's Medical Center Research Institute at UT Southwestern, investigates how stem cells function, regenerate, and interact with their surrounding environment in the bone marrow. His research reveals how leptin receptor-positive cells—key components of the bone marrow niche—regulate hematopoietic stem cell maintenance and regeneration, influence platelet production, and respond to physiological stress like pregnancy. Morrison uncovers a reciprocal relationship between these niche cells and peripheral nerves, showing that disrupting nerve signals impairs bone marrow recovery after chemotherapy or radiation. His work also links retrotransposon activation during pregnancy to increased red blood cell production, with implications for maternal health and transplant medicine. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40449]

Commentary by Dr. Pilar Martin.

In this week's episode we'll learn more about enhanced transplant characteristics; targeting the JAK-STAT pathway with ruxolitinib in patients with adult-onset Still's disease and macrophage activation syndrome; and a pair of trials demonstrating lack of benefit for the anti-CD47 monoclonal antibody magrolimab in newly diagnosed acute myeloid leukemia.Featured ArticlesHeterogeneity of high-potency multilineage hematopoietic stem cells and identification of “Super” transplantabilityRuxolitinib targets JAK-STAT signaling to modulate neutrophil activation in refractory macrophage activation syndromeMagrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 studyThe ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Early Cardiovascular Events in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.

In this week's episode, we'll learn more about social determinants of health that impact access to allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia, or AML; use of megakaryocyte growth factor receptor-based stem cell depletion as part of pretransplant conditioning in ex vivo autologous gene therapy; and identification of an eight-protein risk signature as well as a novel single protein biomarker, soluble oncostatin M receptor, for risk stratification in AML.Featured Articles:Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiacMPL-Based Purification and Depletion of Human Hematopoietic Stem Cells: Implications for Pretransplant ConditioningBlood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes

Commentary by Satish Raj.

In this week's episode we'll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene variants and their association with post-hematopoietic stem cell transplant outcomes in AML; and pathways by which chronic inflammation and oxidative stress may lead to cardiomyopathy in patients with sickle cell disease.Featured Articles:PSTK inhibition activates cGAS-STING, precipitating ferroptotic cell death in leukemic stem cells Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in Acute Myeloid Leukemia 17R-Resolvin D1 Protects Against Sickle Cell Related Inflammatory Cardiomyopathy in Humanized Mice 

Dr. Justin Abbatemarco provides an update on autologous hematopoietic stem cell transplantation in multiple sclerosis. Show reference: https://www.nature.com/articles/s41582-024-01050-x

In this week's episode, we'll learn more about using itacitinib for the prevention of graft vs host disease in haploidentical transplants, diagnosis and management of purpura fulminans, and results of a systematic review seeking evidence for sickle cell crisis-associated mortality in individuals with sickle cell trait. Featured Articles:Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantationHow I diagnose and treat acute infection–associated purpura fulminansSickle cell trait does not cause “sickle cell crisis” leading to exertion-related death: a systematic review

In this podcast, Dr. Marcos de Lima from the Ohio State University, Columbus, OH, USA, and Dr. David I. Marks from the University Hospitals Bristol NHS Trust, Bristol, UK, discuss real-world data obtained from the Center for International Blood and Marrow Transplant Research database to evaluate post-allogeneic hematopoietic stem cell transplantation outcomes in adult patients with acute lymphoblastic leukemia who received inotuzumab ozogamicin. This podcast is published open access in Targeted Oncology and is fully citeable. You can access the original published podcast article through the Targeted Oncology website and by using this link: https://link.springer.com/article/10.1007/s11523-025-01129-5. All conflicts of interest can be found online. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Commentary by Dr. Oscar Calvillo-Argüelles.

Welcome to the second installment of an exclusive 8-part ASTCT Talks series, supported by an educational grant from Sanofi US. In this series, ASTCT President Dr. Corey Cutler speaks with authors from each article in the latest Graft versus Host Disease and Late Effects Following Allogeneic Transplantation Journal collection. In this episode, Dr. Cutler is joined by Dr. Nathaniel S. Treister, a recognized expert in oral medicine, to discuss the intricacies of oral chronic GVHD and its impact on oral health following allogeneic hematopoietic cell transplantation. They explore the diagnostic criteria, effective management strategies, and long-term care considerations for patients, highlighting the importance of both supportive care and multidisciplinary collaboration. For further insights, read Dr. Treister's article, “Oral Chronic Graft-versus-Host Disease and Oral Health after Allogeneic Hematopoietic Cell Transplantation — What the Care Team Needs to Know”, and stay tuned as Dr. Cutler and authors continue to provide a comprehensive guide on cGVHD management through this supplement series.

n this episode, CJ dives deep into the powerful concept of neuroplasticity, the brain's ability to rewire itself and adapt through learning and experience. Neuroplasticity is not just a buzzword; it's a fundamental aspect of how we can improve cognitive performance, longevity, and overall health. CJ ties together biohacking, natural methods, and cutting-edge scientific discoveries to show how we can boost brain function, stave off aging, and optimize our physical health.Key Topics Covered:Cognitive Hacking: Improving focus, memory, creativity, and decision-making are all linked to keeping our brains flexible and sharp. CJ emphasizes that cognitive function directly impacts longevity, and brain health is a gateway to a longer, healthier life.Nootropics: CJ explores nootropics like Modafinil and its refined version, Armodafinil, as smart drugs that boost brain performance, alongside natural alternatives like cold exposure and breathing techniques, such as the Wim Hof Method.Natural Cognitive Boosters: From blueberries and dark leafy greens to mindfulness meditation, CJ offers accessible ways to keep your brain sharp without relying on synthetic compounds.Stem Cells and Aging: CJ breaks down the types of stem cells (e.g., Mesenchymal and Hematopoietic) and how they play a key role in repairing tissue and boosting the immune system. He suggests simple lifestyle changes like resistance training and intermittent fasting to naturally promote stem cell health.Muscle Growth and Anti-Aging: Maintaining muscle mass is crucial as we age. Strength training and anti-inflammatory diets rich in omega-3s can help slow down muscle degradation, while exploring the potential of follistatin for future anti-aging breakthroughs.Telomeres and Longevity: Stress management is essential for protecting telomeres, the protective caps on our DNA that shorten as we age. Practices like meditation, yoga, and spending time in nature can reduce stress and support longevity.Key Takeaways:Neuroplasticity is vital for keeping our brains flexible, and by learning new skills and habits, we keep our cognitive function sharp as we age.Natural cognitive enhancers like sleep, cold exposure, and mindfulness can be as effective as nootropics in boosting brain performance.Stem cell health can be maintained through regular exercise and intermittent fasting, which helps to boost immune function and tissue repair.Muscle maintenance is crucial for longevity; resistance training and anti-inflammatory foods can slow muscle loss and reduce inflammation.Telomere health is directly linked to stress. Reducing chronic stress through mindful practices helps protect your DNA and slow aging.5 Things You Can Start Doing Today:Practice mindfulness meditation to boost creativity, reduce stress, and support brain function.Incorporate berries and leafy greens into your diet to enhance memory and brain health.Start intermittent fasting to regenerate stem cells and improve longevity.Do strength training to maintain muscle mass and slow down the aging process.Prioritize sleep to enhance cognitive function and protect your overall health.Stay curious, and embrace a balanced approach to biohacking for a healthier, longer life!

Hematopoietic progenitor cell (HPC) transplant continues to be used in more and more situations. In this episode, Dr. Brian Adkins outlines the many issues surrounding transfusion support in HPC transplant patients (yes, including the challenge of ABO-incompatible HPC transplants!).

Follow along with our Nailed it Board/OITE Podcast Companion book. Get your copy by clicking here >> https://a.co/d/cr4i8nD  Enjoy another episode from our board review series featuring Dr. Cole and Dr. Woolwine.   This episode is sponsored by the American Academy of Orthopaedic Surgeons: Filled with content that has been vetted by some of the top names in orthopaedics, the AAOS Resident Orthopaedic Core Knowledge (ROCK) program sets the standard for orthopaedic education. Whether ROCK is incorporated into your residency curriculum, or you use it independently as a study tool, the educational content on ROCK is always free to residents. You'll gain the insights and confidence needed to ensure a successful future as a board-certified surgeon who delivers the best patient care. Log on at https://rock.aaos.org/. 

If you've studied the hematopoietic system malignancies—all the leukemias, lymphomas, and plasma cell disorders—you probably feel like you've been hit with the good old medical school fire hose. Now's a good time to take a step back from all the details, make sure that you remember the underlying framework, and pull together some information that connects several different diseases. In this brick, we'll revisit some of the hematopoietic diseases that we often talk about in pairs: acute vs chronic leukemias, benign lymph node diseases vs lymphoma, and low-grade vs high-grade lymphomas. Also, in case you haven't already done this on your own, we'll pull together all the important translocations, their respective diseases, and the reasons why we should remember them. After listening to this AudioBrick, you should be able to: Compare and contrast acute and chronic leukemias. Compare and contrast the morphologic features of benign follicular hyperplasia and follicular lymphoma. Compare and contrast the morphologic and clinical features of low-grade and high-grade lymphomas and give examples of each. Know the following translocations and name the disease (and prognostic significance, if any) associated with each: t(8;21), t(15;17), inv(16), 11q23, FLT3 mutation, t(9;22), t(11;14), t(14;18), and t(8;14). You can also check out the original brick on Hematopoietic Malignancies: Putting It All Together from our Hematology collection, which is available for free. Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including nearly 800 Rx Bricks.  After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology. *** If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts.  It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn how you can access over 150 of our bricks for FREE: https://usmlerx.wpengine.com/free-bricks/

This week's episode will be focusing on hematopoietic growth factors, including G-CSF, TPO agonists, and ESAs. This is another episode in our series on supportive care, and a highly testable and frequently discussed topics on consults and in clinic.

At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!

Commentary by Dr. Catherine Lee & Richard Cheng

“I think the most amazing thing we see is the softening of the skin, which can occur during the first two weeks of the conditioning regimen. The nurses on the floor see it, and I think it's just a tremendous gratification for them to see the results of something right before your eyes,” Tanya Helms, PA-C, from the division of hematological malignancies and cellular therapy at Duke University Medical Center in Durham, NC, told Lenise Taylor, MN, RN, AOCNS®, BMTCN®, oncology clinical specialist at ONS, during a discussion about what oncology nurses should know about transplantation for patients with non-oncologic conditions such as autoimmune disease, how the transplant process differs for non-oncology indications, and the clinical pearls oncology nurses should consider when caring for patients with autoimmune diseases during the transplantation process.  You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0  Earn 0.5 NCPD contact hours of nursing continuing professional development (NCPD), which may be applied to the early post-transplant management and education, treatment modalities, diagnosis, staging and treatment planning, or coordination of care ILNA category, by listening to the full recording and completing an evaluation at myoutcomes.ons.org by September 29, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: The learner will report an increase in knowledge related to hematopoietic stem cell transplantation for scleroderma and other autoimmune diseases.   Episode Notes  Complete this evaluation for free NCPD.  Oncology Nursing Podcast:  Episode 173: Oncology Nurses' Role in Stem Cell Transplants for Pediatric Sickle Cell Disease  Episode 148: Stem Cell Transplant Nursing in the Home Setting  ONS Voice article: What Oncology Nurses Need to Know About Vaccination and Cancer (and other immunocompromised diseases)  Clinical Journal of Oncology Nursing article: Early Intervention With Transplantation Recipients to Improve Access to and Knowledge of Palliative Care  ONS course: Hematopoietic Stem Cell Transplantation  ONS Huddle Card™: Hematopoietic Stem Cell Transplantation  National Scleroderma Foundation  New England Journal of Medicine article about the SCOT trial: Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma  Systemic Sclerosis as an Indication for Autologous Hematopoietic Cell Transplantation: Position Statement from the American Society for Blood and Marrow Transplantation  Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis    To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.    Highlights From Today's Episode  “The goal of treatment for patients with scleroderma is to reset the immune system, and there are three main components of the regimen used at Duke—that's total body radiation, cyclophosphamide, and ATG. This targets all the areas where the immune effector cells live. We also use CD34 selection, which is a process that separates CD34-positive cells from the stem cell product that's collected prior to transplant, to eliminate the possibility of reinfusing activated immune cells back into the patients.” TS 3:18  “For patients with diffuse scleroderma, you want to offer transplant when they have evidence of significant disease, but they're not so compromised that they can't tolerate or have increased risk of complications from the conditioning regimen. Understanding the patient's rate of disease progression is key when determining to transplant.” TS 6:45  “When a patient is referred, we call the patient, and we talk about how the transplant conditioning regimen works to reset the immune system and stop disease progression. We explain the workup visit and go over an example of the timeline needed to collect the cells, admit to the hospital for conditioning, and the recovery process as an outpatient. We want patients to understand the big picture before they ever come to Duke.” TS 7:57  “Some patients come to us significantly disabled by their scleroderma. They may be in a wheelchair, so they require special vehicles for travel. Patients whose hands are severely involved need assistance with their ADLs [activities of daily living].” TS 11:43  “There have been three clinical trials that show autologous transplant improves event-free survival and overall survival and has been shown to decrease all-cause mortality. But it does not repair damaged gastrointestinal, pulmonary, or cardiac tissue. Any fibrosis that has happened is permanent.” TS 12:22  “The most amazing thing we see is the softening of the skin, which can occur during the first two weeks of the conditioning regimen. The nurses on the floor see it, and I think it's just a tremendous gratification for them to see the results of something right before your eyes.” TS 13:01  “Social media has been a huge contributor towards patient self-referrals. Patients are telling their stories on Facebook; patients are asking other questions about how to get referred to a transplant center; and patients whose rheumatologists have not referred them will seek out transplant centers to learn more about transplant for scleroderma.” TS 13:48  “For people with hematologic malignancies, it's all about getting that patient to remission and then transplanting them. . . . These patients have experienced chemotherapy and the adverse effects. They know about low blood counts and fatigue and recovery. They know about central lines and transfusions. The scleroderma patients come to transplantation with progressive disease. They've typically not had blood transfusions, but they are now going to receive total body radiation, chemotherapy, and a stem cell transplant over the next six weeks. And it can be overwhelming. . . . Every day is something new for them to process and learn.” TS 14:56  “Patients become pancytopenic, and they are heavily immunosuppressed. They are on steroids during the conditioning regimen to prevent scleroderma flares during conditioning. These patients have a central line so monitoring for infections, such as assessing vital signs for signs and symptoms of infection, and being aware that steroids can mask a fever.” TS 16:49   

Welcome to Living Well with MS, where we are pleased to welcome Professor Richard Burt as our guest! Professor Burt is a leading expert in hematopoietic stem cell transplantation (HSCT) for autoimmune diseases including MS and has been awarded a number of prestigious accolades. Watch this episode on YouTube here. Keep reading for the key episode takeaways and Professor Burt's bio. Questions and Timestamps 02:35 Could you introduce yourself and tell us about your work with patients with autoimmune conditions and MS? 12:03 What do you think about the idea of flipping the model and offering the most aggressive treatment options to patients first? 16:27 What are the risks of HSCT? 21:18 Can you tell us about the costs associated with stem cell transplantation? 24:13 What type of patients respond best to HSCT? 31:16 Do you see a future where doctors are trained in multiple fields and understand the whole picture of autoimmunity? 38:10 If someone's interested in exploring HSCT, what should they look for in a clinic or physician? 41:47 HSCT has a high upfront cost but how does that compare to being on an MS drug for years or perhaps a lifetime? 53:50 The Dalai Lama wrote the introduction to your book 'Everyday Miracles'. How did that come about? Selected Key Takeaways Randomised controlled trial results for HSCT have been very positive 05:12 “In a randomised trial, [HSCT] was just hands down much better than any [other] drug. All the drugs you use for MS are based on approval for slowing disease activity. That is slowing the number of relapses or slowing the rate of progression of disability but not stopping it or not reversing it. Often you stay on these drugs indefinitely. A transplant, on the other hand, is a one-time treatment and afterwards, you get better, your neurologic disability reverses, nothing else had done that.” It's important to consider the disease trajectory, risks, and benefits of stem cell transplants. 14:02 “MS causes accelerated loss of brain volume, that is brain atrophy. Unfortunately, as we age, we get brain atrophy and a normal, very low, but normal decline. But once you get MS, that decline takes a much sharper drop, and you're losing neural function a lot faster than normal ageing. For some reason, that's not viewed as a sub-acute or semi-emergency situation that you want to reverse. Traditional drugs have mostly just slowed that rate of decline, but it's still faster than what happens with normal ageing. I would think a more aggressive approach up front would be wise, but you always have to remember [the] risk–benefit. If we could do a stem cell transplant with zero risk of mortality, I would say absolutely for everybody. But you can't do that right now.” A medical speciality and institute for autoimmunology could help push the field forward 34:20 “There are 80 different autoimmune diseases that I can think of offhand. They're all “homeless” in different departments like Crohn's disease [which is] in gastroenterology, Scleroderma [which] is in rheumatology, and multiple sclerosis [which] is in neurology. They're all separated [into] different areas. If there was a better organisation, beginning at a federal level with a national institute of autoimmune diseases that supports centres of excellence around the country, that would really help this go forward.” Want to learn more about living a full and happy life with multiple sclerosis?  Sign up to our newsletter to hear our latest tips. More info and links: Visit Professor Burt's website Read Professor Burt's new book on HSCT for autoimmune diseases ‘Everyday Miracles' Check out Professor Burt's medical textbook ‘Hematopoietic Stem Cell Transplantation and Cellular Therapies for Autoimmune Diseases' Find out more about the StarMS trial in the UK New to Overcoming MS? Visit our introductory page  Connect with others following Overcoming MS on the Live Well Hub Visit the Overcoming MS website Follow us on social media: Facebook Instagram YouTube Pinterest Don't miss out:  Subscribe to this podcast and never miss an episode. Listen to our archive of Living Well with MS episodes here. If you like Living Well with MS, please leave a 5-star review. Feel free to share your comments and suggestions for future guests and episode topics by emailing podcast@overcomingms.org. Make sure you sign up to our newsletter to hear our latest tips and news about living a full and happy life with MS. Support us:  If you enjoy this podcast and want to support the ongoing work of Overcoming MS, we would really appreciate it if you could leave a donation here. Every donation, however small, helps us to share the podcast with more people on how to live well with MS. Professor Richard Burt's bio: Professor Richard Burt is a Fulbright Scholar, Professor of Medicine at Scripps Health Care, tenured retired Professor of Medicine at Northwestern University, and CEO of Genani Biotechnology. He endeavored for 35 years, first with animal models and then with some of the world's first clinical trials, to bring the field of stem cell and cellular therapy to the patients' bedsides. Publishing Professor Burt has published more than 145 first-author articles and is the editor of four medical textbooks. He was the first Autoimmune Committee Chairperson for the International Bone Marrow Transplant Registry (IBMTR) and was the principal investigator of a National Institutes of Health (NIH) $10 million multicenter contract to develop stem cell clinical trials for autoimmune diseases. Hematopoietic stem cell transplants Professor Burt performed America's first hematopoietic stem cell transplant (HSCT) for multiple sclerosis (MS), systemic lupus erythematosus (SLE), Crohn's disease (CD), stiff person syndrome (SPS), and chronic inflammatory demyelinating polyneuropathy (CIDP) and published the world's first randomised clinical stem cell transplantation trials for systemic sclerosis and multiple sclerosis. Awards and achievements He has been awarded the Leukemia Scholar of America, the Lupus Foundation of America Fidelitas Award, the van Bekkum Award by the European Society for Blood and Marrow Transplantation, the Distinguished Clinical Achievement Award by the Clinical Research Forum, and the European Group for Blood and Marrow Transplantation Clinical Achievement Award. Professor Burt was presented in Vatican City, Rome, with the “Keys to the Vatican,” was a speaker at the Festival of Thinkers in Leadership in Healthcare in the United Arab Emirates and chaired the biotechnology session at the Baku Azerbaijan International Humanitarian Forum. Professor Burt was recognised by Science Illustrated for accomplishing one of the top 10 medical breakthroughs for the next 10 years and by Scientific American as one of the top 50 individuals for improving humanity and outstanding leadership.

In this week's episode, we'll learn more about the treatment of relapsed and refractory cutaneous T-cell lymphoma with dimethyl fumarate, discuss the use of lipid nanoparticles for ex vivo editing of human hematopoietic cells, and learn more about racial and geographic disparities in lymphoma clinical trials.

In this week's bonus episode of Blood Podcast, your source for innovative ideas and cutting-edge information. In this episode Associate Editor, Dr. John Crispino discusses the Review Series on Hematopoietic Stem Cells with authors, Dr. David Kent and Dr. Jennifer Trowbridge.    

In this week's episode, we'll discuss the findings from a study attempting gene therapy for WHIM syndrome for the first time, learn more about the fate of hematopoietic stem cells after transplantation, and discuss the role of C-terminal FGF23 peptides in iron conservation.

In this episode, we discuss the management of acute toxicities of CAR T-cell therapy, including CRS, ICANS, and HLH with Dr. Michael Jain from Moffitt Cancer Center.Here are some of the key articles we discussed:1. “How I treat refractory CRS and ICANS after CAR T-cell therapy”.      https://pubmed.ncbi.nlm.nih.gov/36989488/ 2. CAR-HEMATOTOX score:     https://pubmed.ncbi.nlm.nih.gov/34166502/ 3. “How I treat cytopenias after CAR T-cell therapy”.     https://pubmed.ncbi.nlm.nih.gov/36800563/ 4. Immune Effector Cell-Associated HLH-Like Syndrome (ASTCT):    https://pubmed.ncbi.nlm.nih.gov/36906275/ 5. ASTCT consensus grading for CRS and ICANS:    https://pubmed.ncbi.nlm.nih.gov/30592986/6. Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy:    https://pubmed.ncbi.nlm.nih.gov/35696759/ 7. Modified EASIX score for predicting CRS and neurotoxicity:    https://pubmed.ncbi.nlm.nih.gov/34432870/

In this week's episode, we will review patients with chronic ITP having clonal expansions of a specific subset of CD8 T cells, called terminally differentiated effector memory T cells, or TEMRA. Next, for patients with diffuse large B-cell lymphomas, use of a so-called dark-zone signature, previously referred to as the double-hit signature, could help refine prognosis. Finally on today's podcast we'll discuss rethinking the role of hematopoietic stem cells following physiologic emergencies such as acute inflammation and blood loss.

The Root Cause Medicine Podcast is created by Rupa Health, the best way to order, track & manage results from 30+ lab companies in one place for free. The Root Cause Medicine Podcast is a weekly one-on-one conversation with renowned medical experts, specialists, and pioneers who are influencing the way we look at our health and wellbeing. This week we're joined by Dr. Richard Burt, Chief of the Division of Immunotherapy, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois. In this episode, Dr. Richard Burt shares his insights on hematopoietic stem cell transplant (HSCT) for autoimmune disorders. For thirty-five years, Dr. Burt dedicated himself to advancing stem cell and cellular therapy, beginning with animal models and, later, some of the world's first clinical trials. He authored over 145 articles, mostly as the first author, and edited four medical textbooks. As the first Autoimmune Committee Chairperson for the International Bone Marrow Transplant Registry (IBMTR), he led the way in developing stem cell clinical trials for autoimmune diseases, securing a National Institute of Health (NIH) $10,000,000 multi-center contract. Dr. Burt performed America's first hematopoietic stem cell transplant (HSCT) for multiple sclerosis (MS), systemic lupus erythematosus (SLE), Crohn's disease (CD), stiff person syndrome (SPS), and chronic inflammatory demyelinating polyneuropathy (CIDP). He also published the world's first randomized clinical stem cell transplantation trials for systemic sclerosis and multiple sclerosis. Dr. Burt's pioneering stem cell work earned him recognition as one of the top 50 people in the world for improving humanity by Scientific American in 2006, along with A1 Gore and Steve Jobs. In 2011, Science Illustrated recognized his stem cell work as one of the top 10 advances of the decade. Key Takeaways: What is a hematopoietic stem cell transplant? Hematopoietic stem cell transplantation (HSCT) is a medical procedure where multipotent stem cells are transplanted into a patient, typically from bone marrow, peripheral blood, or umbilical cord blood. These cells can replicate and produce new, healthy blood cells, which can rejuvenate or repair damaged tissue in different organs, and also help fight viruses and foreign tissue. While leukemia is caused by defects in the blood stem cells themselves, autoimmune diseases arise from defects in the immune cells produced by these stem cells. To treat autoimmune diseases, specialists target the effector cells responsible for the disease and eliminate them, then quickly regenerate healthy cells from the blood stem cell. By using HSCT to replace damaged or defective cells with healthy ones, physicians hope to mitigate the symptoms of autoimmune disorders and promote long-term recovery. This innovative approach to treatment is still undergoing testing and refinement, but it shows great promise in the fight against these debilitating diseases. Finding the optimal transplant regimen for autoimmune diseases If your regimen is too strong, whether it's myeloablative or non-myeloablative, you can have more toxicity and problems. If it's too weak, it's not going to be effective. And so you've got to find that right regimen. When finding the optimal transplant regimen for autoimmune diseases, the aim is to develop a treatment plan that maximizes the benefits of the transplant while minimizing the risks and complications associated with it. An optimal transplant regimen for autoimmune diseases involves selecting the appropriate donor, considering the type of transplant, choosing the right conditioning regimen, and determining the timing and dosing of immunosuppressive medications. Financial toxicity in American healthcare systems Financial toxicity is a growing concern in America, particularly in medical treatments. Unfortunately, this often leads to patients being prescribed expensive treatments that may not be the best option for their specific needs. To achieve successful outcomes with hematopoietic stem cell transplantation, two key factors need to be considered: patient selection and the conditioning regimen used. However, due to the financial pressures facing healthcare providers and institutions, specialists may feel obligated to prescribe expensive treatments, even if they are not necessarily the most appropriate option for the patient. This can be a major source of frustration for patients, who may struggle to afford these treatments or may not receive the care that they truly need. Dr. Burt emphasizes the importance of physicians taking responsibility for their patient's care and being mindful of the financial implications of their recommendations. Rather than being driven solely by financial considerations, doctors should focus on providing the best possible care for their patients. By doing so, they can help to mitigate the effects of financial toxicity and ensure that patients receive the treatments that are best suited to their individual needs.

Commentary by Dr. Valentin Fuster

Dr. Matilde Inglese discusses her article, "Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis". Show References: https://n.neurology.org/content/early/2022/12/21/WNL.0000000000206750

Dr. Shuvro Roy talks with Dr. Matilde Inglese about comparing stem-cell transplants to DMTs in patients with Secondary Progressive MS. Read the related article in Neurology®.

In this episode, we dive into the considerations behind choosing HLA-matched vs. haplo-identical HSCT donors and the clinical innovations that are driving increases in haplo-identical HSCT.

Featuring perspectives from Dr Richard Stone, including the following topics: Current and future trends in the care of patients with acute myeloid leukemia (AML) (0:00) Management of AML with IDH1/2 and FLT3 mutations (17:28) Advances in the treatment of high-risk AML (29:42) Emerging data with novel therapies for AML with targetable mutations (36:53) Hematopoietic stem cell transplantation as a treatment option for patients with relapsed or refractory AML (51:15) Advances in the care of patients with myelodysplastic syndromes (56:19) CME information and select publications

Today, we're talking about a topic that you've told me is the topic that you'd most like me to cover on this podcast -- autologous hematopoietic stem cell transplantation, or HSCT. And I'm dedicating this entire episode of RealTalk MS to a deep dive on the subject with the man who pioneered autologous HSCT as a treatment for relapsing-remitting MS, Dr. Richard Burt. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Autologous HSCT with Dr. Richard Burt  :23 Dr. Richard Burt takes us on a deep dive into autologous HSCT for MS  :57 Share this episode  54:38 Have you downloaded the free RealTalk MS app?  54:59 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/281 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Amazon: Everyday Miracles: Curing Multiple Sclerosis, Scleroderma, and Autoimmune Diseases by Hematopoietic Stem Cell Transplant by Dr. Richard Burt https://www.amazon.com/Everyday-Miracles-Scleroderma-Autoimmune-Hematopoietic/dp/B0BRNTJZ9X/ref=sr_1_1 National MS Society: aHSCT in MS https://nationalmssociety.org/Treating-MS/aHSCT Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 281 Guest: Dr. Richard Burt Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

CME credits: 1.25 Valid until: 22-12-2023 Claim your CME credit at https://reachmd.com/programs/cme/the-role-and-limitations-of-hematopoietic-stem-cell-transplantation-in-farber-disease/14947/ Farber disease is a lysosomal storage disorder characterized by a deficiency of the acid ceramidase enzyme. Abnormal accumulation of ceramide leads to macrophage-driven inflammation and multiple organ system pathologies, impacting bone, cartilage, the immune system, the central nervous system (CNS), lungs, and other organs. It is a progressive disease with profound morbidity and often premature death. Early recognition of core symptoms of Farber disease is necessary for accurate referral and treatment. This program provides an educational framework to shorten delays in diagnosis, and discusses new approaches that can ultimately impact a patient's long-term outcome.

Key papers discussed in the show:1. Landmark paper on HLA-mismatch and survival: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568127/2. HLA-DP and Risk of GVHD: https://www.nejm.org/doi/full/10.1056/NEJMoa15001403. Outcomes of Allogeneic Transplant with HLA-Mismatched Unrelated Donor: https://ascopubs.org/doi/10.1200/JCO.20.035024. Review/perspective on fundamentals of unrelated donors and cord blood units: https://ashpublications.org/blood/article/120/2/259/30405/A-perspective-on-the-selection-of-unrelated-donors5. HLA-DQ heterodimers and HCT: https://ashpublications.org/blood/article-abstract/139/20/3009/484363/HLA-DQ-heterodimers-in-hematopoietic-cell6. PT-Cy as GVHD prophylaxis after HCT: https://pubmed.ncbi.nlm.nih.gov/20124511/7. Comparative outcome of MUD vs Haplo-HCT from Registry data: https://ashpublications.org/blood/article/138/3/273/475738/HLA-haploidentical-vs-matched-unrelated-donor 

Kaylee A. Clark, PharmD describes the basic principles of maintenance therapies after allogeneic HSCT, discusses evidence and guideline recommendations for maintenance therapies after allogeneic HSCT for acute lymphoblastic leukemia and reviews evidence and guideline recommendations for maintenance therapies after allogeneic HSCT for acute myeloid leukemia. For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter! You can also connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd. 

In this latest episode of ASTCT Talks, Dr. Andrés Gómez De León, a physician at the Universidad Autónoma de Nuevo León Hematology Service in Monterrey, Mexico, and Dr. Cristóbal Frutos, who is the Coordinator for the Bone Marrow transplant Unito the Hospital Central Instituto de Previsión Social in Asunción Paraguay, discuss the current state of transplant activities and the importance of having access to cell therapies worldwide. Dr. Frutos presented on this topic during the 2022 Tandem Meetings of ASTCT & CIBMTR.

Betty Hamilton, MD, Interim Director of the Blood and Marrow Transplant (BMT) Program at Cleveland Clinic joins the Cancer Advances podcast to discuss research and findings that were presented at the 2021 American Society of Hematology Annual Meeting (ASH). Listen as Dr. Hamilton discusses graft-versus-host disease and the study that evaluates a new regimen.

Dr. Kelly McNagny is a Professor of Medical Genetics and Biomedical Engineering at the University of British Columbia. His research program is focused on hematopoietic stem cell biology, specifically in understanding the signaling networks that regulate stem cell differentiation and how these cells interact with their microenvironment. He talks about how hematopoietic stem cell differentiation is related to chronic inflammatory disorders, targeting glycosylation in solid tumors, and his international career path.

How can we improve the number of years we can live healthy lives? Jennifer Trowbridge, PhD, shares her recent work looking at hematopoietic stem cell aging. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37590]

How can we improve the number of years we can live healthy lives? Jennifer Trowbridge, PhD, shares her recent work looking at hematopoietic stem cell aging. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37590]

How are hematopoietic stem cells born during the development of the vertebrate embryo? David Traver, PhD explains his work with zebrafish to understand these processes and the role of the somite in instruction of these cells. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 37588]

In this episode, I converse with Dr. Rubul Mout, a Research Fellow at Harvard Medical School and at the Stem Cell Program, Boston Children's Hospital (BCH). Born, brought up, and educated in India, Dr. Mout moved to the United States to pursue his PhD from the University of Massachusetts, Amherst. Prior to joining Harvard/BCH, he was a Washington Research Foundation Innovation Fellow at the Institute for Protein Design, University of Washington. Dr. Mout is the inventor of numerous technologies in gene editing and protein design, and in the last decade he developed a technology for intracellular protein delivery and gene editing in mammalian cells, termed as the ‘E-tag' method, which was in 2020, granted a patent by USPTO (the United States Patent and Trademark Office). At Harvard/BCH, Dr. Mout works to engineer bone marrow stem cells (Hematopoietic stem cells, or HSCs) to cure genetic diseases of blood origin and uses various technologies, including techniques he invented in his prior research, to engineer these HSCs. In particular, he uses patient-derived induced pluripotent stem cells (iPSC) to differentiate them to HSC first, and then to produce and train T-cells that could potentially fight off many diseases. We indulge in a terrific conversation on his magnificent journey through science and life inspired by his innate curiosity; growing up in a poor peasant's family in a far remote corner of Northeast India, near the Assam-Arunachal border; undertaking a majestic quest from Tinsukia to Mumbai to Amherst to Seattle to Boston; inspirational mentors like GK Johori, David Baker, Vincent Rotello, and George Daley; fantastic dedication to scientific outreach and activism; writing outstanding books including a popular bestseller that chronicled his splendid journey; and many more things!!

If you've studied the hematopoietic system malignancies—all the leukemias, lymphomas, and plasma cell disorders—you probably feel like you've been hit with the good old medical school fire hose. Now's a good time to take a step back from all the details, make sure that you remember the underlying framework, and pull together some information that connects several different diseases. In this brick, we'll revisit some of the hematopoietic diseases that we often talk about in pairs: acute vs chronic leukemias, benign lymph node diseases vs lymphoma, and low-grade vs high-grade lymphomas. Also, in case you haven't already done this on your own, we'll pull together all the important translocations, their respective diseases, and the reasons why we should remember them. After listening to this AudioBrick, you should be able to: Compare and contrast acute and chronic leukemias. Compare and contrast the morphologic features of benign follicular hyperplasia and follicular lymphoma. Compare and contrast the morphologic and clinical features of low-grade and high-grade lymphomas and give examples of each. Know the following translocations and name the disease (and prognostic significance, if any) associated with each: t(8;21), t(15;17), inv(16), 11q23, FLT3 mutation, t(9;22), t(11;14), t(14;18), and t(8;14). You can also check out the original brick on Hematopoietic Malignancies: Putting It All Together from our Hematology collection, which is available for free. Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including nearly 800 Rx Bricks.  After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology. *** If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts.  It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn how you can access over 150 of our bricks for FREE: https://usmlerx.wpengine.com/free-bricks/